13M149: Abstracts: Sjögren’s Syndrome – Basic & Clinical Science (1633–1638)

Presenting Author(s)

• HA

  Helena Achten, MD (she/her/hers)

  Ghent University
  Merelbeke, Belgium

  Disclosure information not submitted.
• VB

  Vincent Bouget, MSc

  Scienta Lab
  Gif-sur-Yvette, France

  Disclosure information not submitted.
• SF

  Stephanie Finzel, MD

  University Medical Center Freiburg
  Freiburg, Germany

  Disclosure information not submitted.
• BF

  Benjamin A. Fisher, MD, MBBS

  University of Birmingham
  Birmingham, United Kingdom

  Disclosure information not submitted.
• TP

  Tuyet-Hang Pham, MS

  Horizon Therapeutics plc
  Rockville, MD, United States

  Disclosure information not submitted.
• ES

  Eugene St.Clair, MD

  Duke University Medical Center
  Durham, NC, United States

  Disclosure information not submitted.

Abstract oral session.

Non-CME

Presentations:

• 2:00 PM - 2:10 PM PT

  Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease
  

  Presenting Author: Stephanie Finzel, MD – University Medical Center Freiburg
• 2:10 PM - 2:15 PM PT

  Q&A
  
• 2:15 PM - 2:25 PM PT

  Iscalimab (CFZ533) in Patients with Sjögren’s Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study
  

  Presenting Author: Benjamin A. Fisher, MD, MBBS – University of Birmingham
• 2:25 PM - 2:30 PM PT

  Q&A
  
• 2:30 PM - 2:40 PM PT

  Deep Learning Accurately Predicts Focus Score and Diagnosis of Primary Sjögren Syndrome Using Labial Salivary Gland Biopsies
  

  Presenting Author: Vincent Bouget, MSc – Scienta Lab
• 2:40 PM - 2:45 PM PT

  Q&A
  
• 2:45 PM - 2:55 PM PT

  Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren’s Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study
  

  Presenting Author: Eugene St.Clair, MD – Duke University Medical Center
• 2:55 PM - 3:00 PM PT

  Q&A
  
• 3:00 PM - 3:10 PM PT

  IgG-Fc-N-Sialylation and -Galactosylation in Primary Sjögren’s Syndrome (Pss) in Its Potential as Marker of Disease State and Disease Activity
  

  Presenting Author: Helena Achten, MD (she/her/hers) – Ghent University
• 3:10 PM - 3:15 PM PT

  Q&A
  
• 3:15 PM - 3:25 PM PT

  CD40L Inhibition with Dazodalibep Rapidly Reduces Blood Biomarkers of T and B Cell Costimulation in Subjects with Sjögren’s Having High Disease Activity or High Symptom Burden
  

  Presenting Author: Tuyet-Hang Pham, MS – Horizon Therapeutics plc
• 3:25 PM - 3:30 PM PT

  Q&A